Maryland-Based Vaccine Manufacturer Developing COVID-19 Vaccine That Targets Omicron VariantThe Novavax two-dose shot is made with lab-grown copies of the spike protein that coats the coronavirus.
Gaithersburg-Based NovaVax Initiates Trial For Combination COVID-19 And Flu VaccineThe trial will be conducted in Australia at up to 12 sites and results are expected during the first half of 2022.
Novavax Seeks OK For COVID Vaccine In Needy Countries FirstVaccine maker Novavax announced Thursday it has asked regulators in India, Indonesia and the Philippines to allow emergency use of its COVID-19 vaccine -- offering its shot to some low-income countries before rich ones with ample supplies.
Novavax Announces Promising Late-Stage Covid-19 Vaccine Data, More Than 90% EffectiveNovavax announced late-stage data on Monday showing that their vaccine is more than 90 percent effective against Covid-19 across several variants.
Novavax: Large Study Finds COVID-19 Shot About 90% EffectiveVaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico.
WATCH: Gov. Larry Hogan Tours New Novavax Site In Montgomery CountyGov. Larry Hogan toured the new Novavax Global Headquarters site in Montgomery County, Maryland Thursday morning.
University Of Maryland School Of Medicine Begins Novavax COVID-19 Vaccine Study For Ages 12-17The University of Maryland School of Medicine began the expansion of clinical trials for Novavax COVID-19 vaccine in teenagers aged 12 through 17 this week. 
Novavax Announces Early Results Of Combination Flu, COVID-19 VaccineMaryland-based Novavax announced Monday the early data from its combination flu and covid-19 vaccine.
Novavax Expands COVID Vaccine Phase 3 Clinical Trial To Children Ages 12 to 17Novavax will expand its phase 3 clinical trial of its covid-19 vaccine candidate to children ages 12 to 17. 
Novavax Trials Highlight Maryland's COVID-Fighting ComplexIn the past year, the company has landed nine contracts to manufacture coronavirus-related products for companies, including manufacturing all or part of vaccines for Johnson & Johnson, Novavax and AstraZeneca plc.
Novavax COVID-19 Vaccine Candidate 96.4% Effective In U.K. Trial, Company SaysNovavax announced Thursday its vaccine candidate proved to be 96.4% effective against mild, moderate and severe cases of COVID-19 in a Phase 3 trial in the United Kingdom.